Thorac Cardiovasc Surg 2019; 67(02): 092-097
DOI: 10.1055/s-0038-1660802
Original Cardiovascular
Georg Thieme Verlag KG Stuttgart · New York

Wearable Cardioverter–Defibrillators following Cardiac Surgery—A Single-Center Experience

Jan Heimeshoff
1   Cardiothoracic Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
,
Constanze Merz
1   Cardiothoracic Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
,
Marcel Ricklefs
1   Cardiothoracic Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
,
Felix Kirchhoff
1   Cardiothoracic Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
,
Axel Haverich
1   Cardiothoracic Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
,
Christoph Bara
1   Cardiothoracic Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
,
Christian Kühn
1   Cardiothoracic Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
› Author Affiliations
Further Information

Publication History

18 March 2018

30 April 2018

Publication Date:
20 June 2018 (online)

Abstract

Background A wearable cardioverter–defibrillator (WCD) can terminate ventricular fibrillation and ventricular tachycardias via electrical shock and thus give transient protection from sudden cardiac death. We investigated its role after cardiac surgery.

Methods We retrospectively analyzed all patients who were discharged with a WCD from cardiac surgery department. The WCD was prescribed for patients with a left ventricular ejection fraction (LVEF) of ≤35% or an explanted implantable cardioverter–defibrillator (ICD).

Results A total of 100 patients were included in this study, the majority (n = 59) had received coronary artery bypass graft surgery. The median wearing time of a WCD patient was 23.5 hours per day. LVEF was 28.9 ± 8% after surgery and improved in the follow-up to 36.7 ± 11% (p < 0.001). Three patients were successfully defibrillated. Ten patients experienced ventricular tachycardias. No inappropriate shocks were given. An ICD was implanted in 25 patients after the WCD wearing period.

Conclusion Ventricular arrhythmias occurred in 13% of the investigated patients. LVEF improved significantly after 3 months, and thus a permanent ICD implantation was avoided in several cases. Sternotomy did not impair wearing time of the WCD. A WCD can effectively protect patients against ventricular tachyarrhythmias after cardiac surgery.

Note

The study was presented at the annual meeting of [blinded]. Annual meeting of the German Society for Thoracic and Cardiovascular Surgery (DGTHG) on February 19th, 2018 at Leipzig, Germany.


Limitations

The study provides new data on the use of wearable defibrillators in patients following cardiac surgery, but it is limited due to its retrospective design. The results may be skewed because only 100 patients over the course of 5 years were included which led to a heterogeneous cohort.


 
  • References

  • 1 Appoo J, Norris C, Merali S. , et al. Long-term outcome of isolated coronary artery bypass surgery in patients with severe left ventricular dysfunction. Circulation 2004; 110 (11) (Suppl. 01) II13-II17
  • 2 Rao MP, Al-Khatib SM, Pokorney SD. , et al; STICH Trial Investigators. Sudden cardiac death in patients with ischemic heart failure undergoing coronary artery bypass grafting: results from the STICH randomized clinical trial (Surgical Treatment for Ischemic Heart Failure). Circulation 2017; 135 (12) 1136-1144
  • 3 Kaul TK, Fields BL, Riggins LS, Wyatt DA, Jones CR. Ventricular arrhythmia following successful myocardial revascularization: incidence, predictors and prevention. Eur J Cardiothorac Surg 1998; 13 (06) 629-636
  • 4 Moss AJ, Zareba W, Hall WJ. , et al; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346 (12) 877-883
  • 5 Moss AJ, Hall WJ, Cannom DS. , et al; Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335 (26) 1933-1940
  • 6 Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004; 292 (23) 2874-2879
  • 7 Priori SG, Blomström-Lundqvist C, Mazzanti A. , et al; ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2015; 36 (41) 2793-2867
  • 8 ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death—executive summary. Circulation 2006; 114: 1088-1132
  • 9 Bax JJ, Visser FC, Poldermans D. , et al. Relationship between preoperative viability and postoperative improvement in LVEF and heart failure symptoms. J Nucl Med 2001; 42 (01) 79-86
  • 10 Søraas CL, Larstorp AC, Mangschau A, Tønnessen T, Kjeldsen SE, Bjørnerheim R. Echocardiographic demonstration of improved myocardial function early after coronary artery bypass graft surgery. Interact Cardiovasc Thorac Surg 2011; 12 (06) 946-951
  • 11 Kutyifa V, Moss AJ, Klein H. , et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation 2015; 132 (17) 1613-1619
  • 12 Wäßnig NK, Günther M, Quick S. , et al. Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circulation 2016; 134 (09) 635-643
  • 13 Piccini Sr JP, Allen LA, Kudenchuk PJ, Page RL, Patel MR, Turakhia MP. ; American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death: a science advisory from the American Heart Association. Circulation 2016; 133 (17) 1715-1727
  • 14 Epstein AE, Abraham WT, Bianco NR. , et al. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction. J Am Coll Cardiol 2013; 62 (21) 2000-2007
  • 15 Sjöblom J, Muhrbeck J, Witt N, Alam M, Frykman-Kull V. Evolution of left ventricular ejection fraction after acute myocardial infarction: implications for implantable cardioverter-defibrillator eligibility. Circulation 2014; 130 (09) 743-748
  • 16 Klein HU, Goldenberg I, Moss AJ. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. Eur Heart J 2013; 34 (29) 2230-2242
  • 17 Ellenbogen KA, Koneru JN, Sharma PS, Deshpande S, Wan C, Szymkiewicz SJ. Benefit of the wearable cardioverter-defibrillator in protecting patients after implantable-cardioverter defibrillator explant. JACC Clin Electrophysiol 2017; 3: 243-250
  • 18 Castro L, Pecha S, Linder M. , et al. The wearable cardioverter defibrillator as a bridge to reimplantation in patients with ICD or CRT-D-related infections. J Cardiothorac Surg 2017; 12 (01) 99
  • 19 Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely implantable cardioverter/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter/defibrillator-The PROLONG study. J Am Heart Assoc 2017; 6 (01) e004512
  • 20 Ender J, Borger MA, Scholz M. , et al. Cardiac surgery fast-track treatment in a postanesthetic care unit: six-month results of the Leipzig fast-track concept. Anesthesiology 2008; 109 (01) 61-66
  • 21 Pack QR, Dudycha KJ, Roschen KP, Thomas RJ, Squires RW. Safety of early enrollment into outpatient cardiac rehabilitation after open heart surgery. Am J Cardiol 2015; 115 (04) 548-552